Review





Similar Products

cdk4 6i  (MedChemExpress)
97
MedChemExpress cdk4 6i
Cdk4 6i, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cdk4 6i/product/MedChemExpress
Average 97 stars, based on 1 article reviews
cdk4 6i - by Bioz Stars, 2026-02
97/100 stars
  Buy from Supplier
cdk4 6 inhibitors  (MedChemExpress)
97
MedChemExpress cdk4 6 inhibitors
Cdk4 6 Inhibitors, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cdk4 6 inhibitors/product/MedChemExpress
Average 97 stars, based on 1 article reviews
cdk4 6 inhibitors - by Bioz Stars, 2026-02
97/100 stars
  Buy from Supplier
palbociclib (cdk4/6 inhibitor)  (Pfizer Inc)
90
Pfizer Inc palbociclib (cdk4/6 inhibitor)
In vitro analysis of mouse BC cell lines derived from K5-positive cells isolated from DKO (4K5; top) and QKO (K5.6; bottom) tumors: (A) sensitivity to <t>palbociclib</t> assessed by XTT assays. Data are presented as mean ± SEM; (B) Cell-cycle changes following palbociclib treatment for 48 hours at the IC 50 analyzed by flow cytometry; (C) Induction of PD-L1 expression after palbociclib treatment, depicting the percentage of live cells with high PD-L1 expression (left axis) and the mean fluorescence intensity (MFI) of PD-L1 (right axis), as assessed by flow cytometry. In B and C, data are presented as mean ± SD from three independent experiments, with the average value of each experiment shown as a single data point. D. In vivo evaluation of palbociclib monotherapy or combined with avelumab (anti-PD-L1) using immunocompetent syngeneic graft models of BC (DKO-K5, top; QKO-K5, bottom). Spider plots show normalized tumor growth curves for each treatment group relative to baseline. The dotted line indicates the threshold for non-responders, defined as half the average tumor volume of the control group. R = responders. E. Comparison of normalized tumor volumes (relative to baseline) between treatment groups at mid-treatment and the end of treatment for both models. Data from each individual are shown, along with the mean ± SD. C = control; P = palbociclib; A = avelumab; P+A = combination palbociclib plus avelumab. ns = not significant; *p-value< 0.05; **p- value< 0.01; ***p-value< 0.001; ****p-value< 0.0001.
Palbociclib (Cdk4/6 Inhibitor), supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/palbociclib (cdk4/6 inhibitor)/product/Pfizer Inc
Average 90 stars, based on 1 article reviews
palbociclib (cdk4/6 inhibitor) - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
cdk4/6 inhibitor palbociclib  (Cayman Chemical)
90
Cayman Chemical cdk4/6 inhibitor palbociclib
In vitro analysis of mouse BC cell lines derived from K5-positive cells isolated from DKO (4K5; top) and QKO (K5.6; bottom) tumors: (A) sensitivity to <t>palbociclib</t> assessed by XTT assays. Data are presented as mean ± SEM; (B) Cell-cycle changes following palbociclib treatment for 48 hours at the IC 50 analyzed by flow cytometry; (C) Induction of PD-L1 expression after palbociclib treatment, depicting the percentage of live cells with high PD-L1 expression (left axis) and the mean fluorescence intensity (MFI) of PD-L1 (right axis), as assessed by flow cytometry. In B and C, data are presented as mean ± SD from three independent experiments, with the average value of each experiment shown as a single data point. D. In vivo evaluation of palbociclib monotherapy or combined with avelumab (anti-PD-L1) using immunocompetent syngeneic graft models of BC (DKO-K5, top; QKO-K5, bottom). Spider plots show normalized tumor growth curves for each treatment group relative to baseline. The dotted line indicates the threshold for non-responders, defined as half the average tumor volume of the control group. R = responders. E. Comparison of normalized tumor volumes (relative to baseline) between treatment groups at mid-treatment and the end of treatment for both models. Data from each individual are shown, along with the mean ± SD. C = control; P = palbociclib; A = avelumab; P+A = combination palbociclib plus avelumab. ns = not significant; *p-value< 0.05; **p- value< 0.01; ***p-value< 0.001; ****p-value< 0.0001.
Cdk4/6 Inhibitor Palbociclib, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cdk4/6 inhibitor palbociclib/product/Cayman Chemical
Average 90 stars, based on 1 article reviews
cdk4/6 inhibitor palbociclib - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
cdk4 6 inhibitor palbociclib  (MedChemExpress)
97
MedChemExpress cdk4 6 inhibitor palbociclib
In vitro analysis of mouse BC cell lines derived from K5-positive cells isolated from DKO (4K5; top) and QKO (K5.6; bottom) tumors: (A) sensitivity to <t>palbociclib</t> assessed by XTT assays. Data are presented as mean ± SEM; (B) Cell-cycle changes following palbociclib treatment for 48 hours at the IC 50 analyzed by flow cytometry; (C) Induction of PD-L1 expression after palbociclib treatment, depicting the percentage of live cells with high PD-L1 expression (left axis) and the mean fluorescence intensity (MFI) of PD-L1 (right axis), as assessed by flow cytometry. In B and C, data are presented as mean ± SD from three independent experiments, with the average value of each experiment shown as a single data point. D. In vivo evaluation of palbociclib monotherapy or combined with avelumab (anti-PD-L1) using immunocompetent syngeneic graft models of BC (DKO-K5, top; QKO-K5, bottom). Spider plots show normalized tumor growth curves for each treatment group relative to baseline. The dotted line indicates the threshold for non-responders, defined as half the average tumor volume of the control group. R = responders. E. Comparison of normalized tumor volumes (relative to baseline) between treatment groups at mid-treatment and the end of treatment for both models. Data from each individual are shown, along with the mean ± SD. C = control; P = palbociclib; A = avelumab; P+A = combination palbociclib plus avelumab. ns = not significant; *p-value< 0.05; **p- value< 0.01; ***p-value< 0.001; ****p-value< 0.0001.
Cdk4 6 Inhibitor Palbociclib, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cdk4 6 inhibitor palbociclib/product/MedChemExpress
Average 97 stars, based on 1 article reviews
cdk4 6 inhibitor palbociclib - by Bioz Stars, 2026-02
97/100 stars
  Buy from Supplier
cdk4 inhibitor palbociclib s4482  (Selleck Chemicals)
90
Selleck Chemicals cdk4 inhibitor palbociclib s4482
In vitro analysis of mouse BC cell lines derived from K5-positive cells isolated from DKO (4K5; top) and QKO (K5.6; bottom) tumors: (A) sensitivity to <t>palbociclib</t> assessed by XTT assays. Data are presented as mean ± SEM; (B) Cell-cycle changes following palbociclib treatment for 48 hours at the IC 50 analyzed by flow cytometry; (C) Induction of PD-L1 expression after palbociclib treatment, depicting the percentage of live cells with high PD-L1 expression (left axis) and the mean fluorescence intensity (MFI) of PD-L1 (right axis), as assessed by flow cytometry. In B and C, data are presented as mean ± SD from three independent experiments, with the average value of each experiment shown as a single data point. D. In vivo evaluation of palbociclib monotherapy or combined with avelumab (anti-PD-L1) using immunocompetent syngeneic graft models of BC (DKO-K5, top; QKO-K5, bottom). Spider plots show normalized tumor growth curves for each treatment group relative to baseline. The dotted line indicates the threshold for non-responders, defined as half the average tumor volume of the control group. R = responders. E. Comparison of normalized tumor volumes (relative to baseline) between treatment groups at mid-treatment and the end of treatment for both models. Data from each individual are shown, along with the mean ± SD. C = control; P = palbociclib; A = avelumab; P+A = combination palbociclib plus avelumab. ns = not significant; *p-value< 0.05; **p- value< 0.01; ***p-value< 0.001; ****p-value< 0.0001.
Cdk4 Inhibitor Palbociclib S4482, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cdk4 inhibitor palbociclib s4482/product/Selleck Chemicals
Average 90 stars, based on 1 article reviews
cdk4 inhibitor palbociclib s4482 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
cdk4/6 inhibitor palbociclib  (Selleck Chemicals)
90
Selleck Chemicals cdk4/6 inhibitor palbociclib
In vitro analysis of mouse BC cell lines derived from K5-positive cells isolated from DKO (4K5; top) and QKO (K5.6; bottom) tumors: (A) sensitivity to <t>palbociclib</t> assessed by XTT assays. Data are presented as mean ± SEM; (B) Cell-cycle changes following palbociclib treatment for 48 hours at the IC 50 analyzed by flow cytometry; (C) Induction of PD-L1 expression after palbociclib treatment, depicting the percentage of live cells with high PD-L1 expression (left axis) and the mean fluorescence intensity (MFI) of PD-L1 (right axis), as assessed by flow cytometry. In B and C, data are presented as mean ± SD from three independent experiments, with the average value of each experiment shown as a single data point. D. In vivo evaluation of palbociclib monotherapy or combined with avelumab (anti-PD-L1) using immunocompetent syngeneic graft models of BC (DKO-K5, top; QKO-K5, bottom). Spider plots show normalized tumor growth curves for each treatment group relative to baseline. The dotted line indicates the threshold for non-responders, defined as half the average tumor volume of the control group. R = responders. E. Comparison of normalized tumor volumes (relative to baseline) between treatment groups at mid-treatment and the end of treatment for both models. Data from each individual are shown, along with the mean ± SD. C = control; P = palbociclib; A = avelumab; P+A = combination palbociclib plus avelumab. ns = not significant; *p-value< 0.05; **p- value< 0.01; ***p-value< 0.001; ****p-value< 0.0001.
Cdk4/6 Inhibitor Palbociclib, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cdk4/6 inhibitor palbociclib/product/Selleck Chemicals
Average 90 stars, based on 1 article reviews
cdk4/6 inhibitor palbociclib - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
cdk4/6 inhibitor palbociclib s4482  (Selleck Chemicals)
90
Selleck Chemicals cdk4/6 inhibitor palbociclib s4482
In vitro analysis of mouse BC cell lines derived from K5-positive cells isolated from DKO (4K5; top) and QKO (K5.6; bottom) tumors: (A) sensitivity to <t>palbociclib</t> assessed by XTT assays. Data are presented as mean ± SEM; (B) Cell-cycle changes following palbociclib treatment for 48 hours at the IC 50 analyzed by flow cytometry; (C) Induction of PD-L1 expression after palbociclib treatment, depicting the percentage of live cells with high PD-L1 expression (left axis) and the mean fluorescence intensity (MFI) of PD-L1 (right axis), as assessed by flow cytometry. In B and C, data are presented as mean ± SD from three independent experiments, with the average value of each experiment shown as a single data point. D. In vivo evaluation of palbociclib monotherapy or combined with avelumab (anti-PD-L1) using immunocompetent syngeneic graft models of BC (DKO-K5, top; QKO-K5, bottom). Spider plots show normalized tumor growth curves for each treatment group relative to baseline. The dotted line indicates the threshold for non-responders, defined as half the average tumor volume of the control group. R = responders. E. Comparison of normalized tumor volumes (relative to baseline) between treatment groups at mid-treatment and the end of treatment for both models. Data from each individual are shown, along with the mean ± SD. C = control; P = palbociclib; A = avelumab; P+A = combination palbociclib plus avelumab. ns = not significant; *p-value< 0.05; **p- value< 0.01; ***p-value< 0.001; ****p-value< 0.0001.
Cdk4/6 Inhibitor Palbociclib S4482, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cdk4/6 inhibitor palbociclib s4482/product/Selleck Chemicals
Average 90 stars, based on 1 article reviews
cdk4/6 inhibitor palbociclib s4482 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


In vitro analysis of mouse BC cell lines derived from K5-positive cells isolated from DKO (4K5; top) and QKO (K5.6; bottom) tumors: (A) sensitivity to palbociclib assessed by XTT assays. Data are presented as mean ± SEM; (B) Cell-cycle changes following palbociclib treatment for 48 hours at the IC 50 analyzed by flow cytometry; (C) Induction of PD-L1 expression after palbociclib treatment, depicting the percentage of live cells with high PD-L1 expression (left axis) and the mean fluorescence intensity (MFI) of PD-L1 (right axis), as assessed by flow cytometry. In B and C, data are presented as mean ± SD from three independent experiments, with the average value of each experiment shown as a single data point. D. In vivo evaluation of palbociclib monotherapy or combined with avelumab (anti-PD-L1) using immunocompetent syngeneic graft models of BC (DKO-K5, top; QKO-K5, bottom). Spider plots show normalized tumor growth curves for each treatment group relative to baseline. The dotted line indicates the threshold for non-responders, defined as half the average tumor volume of the control group. R = responders. E. Comparison of normalized tumor volumes (relative to baseline) between treatment groups at mid-treatment and the end of treatment for both models. Data from each individual are shown, along with the mean ± SD. C = control; P = palbociclib; A = avelumab; P+A = combination palbociclib plus avelumab. ns = not significant; *p-value< 0.05; **p- value< 0.01; ***p-value< 0.001; ****p-value< 0.0001.

Journal: bioRxiv

Article Title: Cell-of-origin and genetic drivers define advanced bladder cancer subtypes and potential therapeutic response in mouse models

doi: 10.1101/2025.07.14.664768

Figure Lengend Snippet: In vitro analysis of mouse BC cell lines derived from K5-positive cells isolated from DKO (4K5; top) and QKO (K5.6; bottom) tumors: (A) sensitivity to palbociclib assessed by XTT assays. Data are presented as mean ± SEM; (B) Cell-cycle changes following palbociclib treatment for 48 hours at the IC 50 analyzed by flow cytometry; (C) Induction of PD-L1 expression after palbociclib treatment, depicting the percentage of live cells with high PD-L1 expression (left axis) and the mean fluorescence intensity (MFI) of PD-L1 (right axis), as assessed by flow cytometry. In B and C, data are presented as mean ± SD from three independent experiments, with the average value of each experiment shown as a single data point. D. In vivo evaluation of palbociclib monotherapy or combined with avelumab (anti-PD-L1) using immunocompetent syngeneic graft models of BC (DKO-K5, top; QKO-K5, bottom). Spider plots show normalized tumor growth curves for each treatment group relative to baseline. The dotted line indicates the threshold for non-responders, defined as half the average tumor volume of the control group. R = responders. E. Comparison of normalized tumor volumes (relative to baseline) between treatment groups at mid-treatment and the end of treatment for both models. Data from each individual are shown, along with the mean ± SD. C = control; P = palbociclib; A = avelumab; P+A = combination palbociclib plus avelumab. ns = not significant; *p-value< 0.05; **p- value< 0.01; ***p-value< 0.001; ****p-value< 0.0001.

Article Snippet: Palbociclib (CDK4/6 inhibitor) and avelumab (human anti-PD-L1 that recognized murine epitope) were provided by Pfizer SLU España (CPT Grant Request ID: 60314347, Project ID: WI235570).

Techniques: In Vitro, Derivative Assay, Isolation, Flow Cytometry, Expressing, Fluorescence, In Vivo, Control, Comparison